top of page
Biotech Stories, News & Events

Similar Stories from FIB

Biotechnology plays a crucial role in the bioeconomy
20/03/24
Biotechnology plays a crucial role in the bioeconomy
Finnish Company Tenboron Develops Groundbreaking Cancer Treatment
06/03/24
Finnish Company Tenboron Develops Groundbreaking Cancer Treatment
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN (2)
01/02/24
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN (2)
Team AlgaLab is the winner of the fifth BioFinland Pitching Competition
01/10/23
Team AlgaLab is the winner of the fifth BioFinland Pitching Competition

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN (2)

Press release Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle.

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN

The combined Group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Product, from preclinical to clinical development and commercial phases. Leveraging a joint 40-year track record, expertise, capabilities, and financial strength, the Group will position itself as a leading pan-European independent biologics CDMO, aiming to spearhead the development of drugs tackling patients’ unmet clinical needs.


Comments